Cancer vaccines

Expert Opinion on Therapeutic Targets

Volumn 8, Issue 6, 2004, Pages 521-525

  Bonnefoy, Jean Yves ^a  

^a Cancerpole Lyon Rhône Alpes ^*  (France)

Author keywords

B cells; Biotherapy; Cytotoxic T lymphocytes (CTLs); IL; Immunotherapy; Natural killer cells; T cells; T helper (TH); Vaccine

Indexed keywords

BCG VACCINE; BCR ABL PROTEIN; CANCER VACCINE; CYTOKINE; DNA VACCINE; EPSTEIN BARR VIRUS ANTIGEN; GLYCOPROTEIN GP 100; HYBRID PROTEIN; INTERLEUKIN 2; K RAS PROTEIN; MELANOMA ANTIGEN; MONOCLONAL ANTIBODY; MONOPHENOL MONOOXYGENASE; MUCIN 1; NAKED DNA; PEPTIDE; PICIBANIL; PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN; PROTEIN E6; PROTEIN E7; PROTEIN P53; TRANSCRIPTION FACTOR FKHR; TUMOR ANTIGEN; TUMOR CELL VACCINE; VIRUS PROTEIN; VIRUS VECTOR;

ADJUVANT THERAPY; ANTIBODY PRODUCTION; CANCER MODEL; DENDRITIC CELL; DRUG POTENTIATION; HUMAN; IMMUNE RESPONSE; IMMUNE STATUS; IMMUNE SYSTEM; IMMUNOLOGICAL TOLERANCE; NONHUMAN; REVIEW; RISK ASSESSMENT; RISK FACTOR; SYSTEMATIC REVIEW; TUMOR ESCAPE;

ADENOVIRIDAE; ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGEN PRESENTATION; ANTIGENS, NEOPLASM; BIOLOGICAL MARKERS; CANCER VACCINES; DENDRITIC CELLS; HUMANS; IMMUNE TOLERANCE; IMMUNIZATION; IMMUNOCOMPROMISED HOST; NEOPLASMS; NEOPLASMS, EXPERIMENTAL; POXVIRIDAE; T-LYMPHOCYTES, CYTOTOXIC; TUMOR ESCAPE; VACCINIA VIRUS;

EID: 11144282443     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.8.6.521     Document Type: Review

References (19)

1. BERZOFSKY JA, TERABE M, OH S et al.: Progress on new vaccine strategies for the immunotherapy and prevention of cancer. J. Clin. Invest. (2004) 113:1515-1525.
2. YU Z, RESTIFO NP: Cancer vaccines: progress reveals new complexities. J. Clin Invest. (2002) 110:289-294.
3. WALDMANN TA: Immunotherapy: past, present and future. Nat. Med. (2003) 9:269-277.
4. GILBOA E: The promise of cancer vaccines. Cancer (2004) 4:401-411.
5. FINN OJ: Cancer vaccines: between the idea and the reality. Nat. Rev. Immunol. (2003) 3:630-641.
6. MORSE MA, CLAY TM, LYERLY HK: Handbook of cancer vaccines Humana Press, Totowa, USA (2004).
7. ROSENBERG SA: Shedding light on immunotherapy for cancer. N. Engl. J. Med. (2004) 350:1461-1463.
8. TERABE M, BERZOFSKY JA: Immunoregulatory T cells in tumor immunity. Curr. Opin. Immunol. (2004) 16:157-162.
9. JANSSEN EM, LEMMENS EE, WOLFE T et al.: CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes. Nature (2003) 421:852-856.
10. SHEDLOCK DJ, SHEN H: Requirement for CD4 T cell help in generating functional CD8 T cell memory. Science (2003) 300 337-339.
11. GETT AV, SALLUSTO F, LANZAVECCHIA A, GEGINAT J: T cell fitness determined by signal strength. Nat. Immunol. (2003) 4 355-360.
12. SALGIA R, LYNCH T, SKARIN A et al.: Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma. J. Clin. Oncol. (2003) 21:624-630.
13. PARMIANI G, CASTELLI C, DALERBE P et al.: Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going? J. Natl. Cancer. Inst. (2002) 94:805-818.
14. SALIT RB, KAST WM, VELDERS MP: Ins and outs of clinical trials with peptide-based vaccines. Front. Biosci. (2002) 7 e204-e213.
15. SMITH JW, WALKER EB, FOX BA et al.: Adjuvant immunization of HLA-A2-positive melanoma patients with a modified gp100 peptide induces peptide-specific CD8+ T-cell responses. J. Clin. Oncol. (2003) 21:1562-1573.
16. SCHULER G, SCHULER-THURNER B, STEINMAN RM: The use of dendritic cells in cancer immunotherapy. Curr. Opin. Immunol. (2003) 15:138-147.
17. STIFT A, FRIEDL J, DUBSKY P et al.: Dendritic cell-based vaccination in solid cancer. J. Clin. Oncol. (2003) 21:135-142.
18. WEBER J, SONDAK VK, SCOTLAND R et al.: Granulocyte-macrophage-colony-stimulating factor added to a multipeptide vaccine for resected Stage II melanoma. Cancer (2003) 97 186-200.
19. MAPARA MY, SYKES M: Tolerance and cancer: mechanisms of tumor evasion and strategies for breaking tolerance. J. Clin. Oncol. (2004) 22:1136-1151.